Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + pegylated liposomal doxorubicin + dexamethasone
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
"RDD" is a combination drug regimen comprising lenalidomide, pegylated liposomal doxorubicin, and dexamethasone. Lenalidomide is an immunomodulatory drug (IMiD) that exerts direct cytotoxic effects and modulates the immune system by influencing cytokine production, T cell initiation, antigen presentation by dendritic cells, regulatory T cell inhibition, and natural killer cell activity, as well as affecting osteoclasts. Pegylated liposomal doxorubicin is an anthracycline topoisomerase II inhibitor. Dexamethasone is a synthetic corticosteroid. This regimen is being investigated for the treatment of multiple myeloma.
- Other names
- RDD regimen
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNACRBN (Cereblon)
Beyond the preview
Go deeper on lenalidomide + pegylated liposomal doxorubicin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + pegylated liposomal doxorubicin + dexamethasone.